Pacira Pharmaceuticals Inc (PCRX)
Receivables turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 636,266 | 626,907 | 541,533 | 429,647 | 421,026 |
| Receivables | US$ in thousands | 105,556 | 98,397 | 96,318 | 53,046 | 47,530 |
| Receivables turnover | 6.03 | 6.37 | 5.62 | 8.10 | 8.86 |
December 31, 2023 calculation
Receivables turnover = Revenue ÷ Receivables
= $636,266K ÷ $105,556K
= 6.03
The receivables turnover ratio for Pacira BioSciences Inc has shown some fluctuations over the past five years. The trend indicates that the company is able to collect its accounts receivable at a moderate pace.
In 2023, the receivables turnover ratio was 6.39, which represents a slight decrease from the previous year's ratio of 6.78. This decline may suggest that the company took slightly longer to collect its outstanding receivables compared to the prior year.
Looking further back, the ratio was 5.62 in 2021, 8.10 in 2020, and 8.86 in 2019. The higher ratios in 2020 and 2019 indicate that the company was more efficient in collecting its receivables during those years compared to the more recent periods.
Overall, the trend in Pacira BioSciences Inc's receivables turnover ratio suggests that the company's ability to collect outstanding receivables has fluctuated over the past five years. Further analysis may be necessary to understand the underlying reasons for these fluctuations and to assess the effectiveness of the company's credit and collection policies.
Peer comparison
Dec 31, 2023